NCT00371501

Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus

Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Tuen Mun Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).

Detailed description

To study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus. Subclinical atherosclerosis is assessed by ultrasound study of the carotid vessels and CT scan of the coronary arteries for calcium scores. Blood markers of endothelial activation will also be studied.

Conditions

• Atherosclerosis
• Thromboembolism
• Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	Rosuvastatin	10mg/day
DRUG	placebo	one tablet/day
DRUG	aspirin	80mg/day
DRUG	placebo	placebo

Timeline

• Start date: 2006-06-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2006-09-04
• Last updated: 2010-09-16

Locations

1 site across 1 country: Hong Kong